Pfizer CFO Dave Denton to Exit August 15; Company Reaffirms FY26 Guidance
Summary
Pfizer announced that CFO Dave Denton will depart on August 15, 2026, with Cecile Guegan stepping in as interim CFO while the company searches for a permanent replacement. This executive change for a company of Pfizer's scale introduces uncertainty, which led to a premarket stock decline. The company also reaffirmed its full-year 2026 financial guidance, which was initially provided on May 5th, indicating no change to its outlook despite the leadership transition. Investors will be watching for updates on the permanent CFO search.
At the time of this announcement, PFE was trading at $25.25 on NYSE in the Life Sciences sector, with a market capitalization of approximately $143.7B. The 52-week trading range was $23.11 to $28.75. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.